Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?

Group 1 - Bright Minds Biosciences Inc. (DRUG) closed at $38.89, with a 9.6% gain over the past four weeks, and a mean price target of $83.25 suggests an upside potential of 114.1% [1] - The mean estimate includes four short-term price targets with a standard deviation of $7.68, indicating variability among analysts; the lowest estimate is $75.00 (92.9% increase), while the highest is $93.00 (139.1% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 9.7% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - DRUG has a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a solid potential upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does provide a directional guide for price movement [14]